List of Ameluz drug patents
Ameluz is owned by Biofrontera.
Ameluz contains Aminolevulinic Acid Hydrochloride.
Ameluz has a total of 2 drug patents out of which 0 drug patents have expired.
Ameluz was authorised for market use on 10 May, 2016.
Ameluz is available in gel;topical dosage forms.
Ameluz can be used as topical lesion-directed and field-directed treatment of actinic keratosis of the face and scalp with photodynamic therapy by positioning an illumination device in an appropriate distance and illuminating the treatment area with narrowband red light.
The generics of Ameluz are possible to be released after 15 October, 2040.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11540981 | BIOFRONTERA | Nanoemulsion formulation with improved stability and cell penetration |
Feb, 2028
(4 years from now) | |
| US11235169 | BIOFRONTERA | Illumination device for photodynamic therapy, method for treating a skin disease and method for operating an illumination device |
Oct, 2040
(17 years from now) | |
Drugs and Companies using AMINOLEVULINIC ACID HYDROCHLORIDE ingredient
Market Authorisation Date: 10 May, 2016
Treatment: Topical lesion-directed and field-directed treatment of actinic keratosis of the face and scalp with photodynamic therapy by positioning an illumination device in an appropriate distance and illuminat...
Dosage: GEL;TOPICAL
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic